Trial Profile
Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 02 Mar 2023 Status changed from active, no longer recruiting to completed.
- 26 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 09 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2021.